Wird geladen...
Human CD59 inhibitor sensitizes rituximab resistant lymphoma cells to complement-mediated cytolysis
Rituximab efficacy in cancer therapy depends in part on induction of complement-dependent cytotoxicity (CDC). Human CD59 (hCD59) is a key complement regulatory protein that restricts the formation of the membrane attack complex, thereby inhibiting induction of CDC. hCD59 is highly expressed in B-cel...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3622284/ https://ncbi.nlm.nih.gov/pubmed/21252115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-3016 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|